[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"varicella-chickenpox\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:varicella-chickenpox":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,71,94,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100624870","phase-3-skyvaricella-nbp608-vaccine-with-lower-potencies-in-healthy-children-aged-12-months-to-12-years-100624870",false,"NCT07415252","SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years","A Phase III, Randomized, Double-blinded, Active-controlled, Multinational, Multicenter Study to Assess the Safety and Immunogenicity of a Two-dose Regimen of SKYVaricella® (NBP608) in Children Aged 12 Months to 12 Years","Inclusion Criteria:\n\nAge\n\n1. Participant must be ≥12 months to ≤12 years of age, at the time of informed consent.\n\n   Type of Participant and Disease Characteristics\n2. Participant is healthy or medically stable, as determined by the investigator through medical history, physical examination, and overall clinical assessment.\n\n   \\* Medically stable condition is defined as no significant change in therapy and no hospitalization for worsening disease within 8 weeks prior to the first study vaccination\n3. Participant's parents\u002FLARs are able and willing to comply with all study procedures and attend all scheduled visits.\n\n   Sex and Contraceptive\u002FBarrier Requirements\n4. Female participants of childbearing potential (i.e., post-menarcheal females) must agree to maintain complete sexual abstinence from heterosexual intercourse, from at least 4 weeks prior to the first study vaccination and through 12 weeks following the second study vaccination (Visit 5).\n5. Female participants of a childbearing potential must have a negative urine pregnancy test at screening; pregnancy testing is not required for those not of childbearing potential.\n\n   Informed Consent\u002FAssent\n6. Participant's parents\u002FLARs are capable of providing signed informed consent, including agreement to comply with the requirements and restrictions specified in this protocol and in the informed consent form (ICF), before initiation of any study-specific procedures. Where applicable, the participant must also be able to provide written assent in accordance with local regulations and IRB\u002FIEC requirements.\n\nExclusion Criteria:\n\nMedical Conditions\n\n1. Any clinically significant respiratory symptoms (e.g., cough, sore throat), febrile illness (tympanic temperature \\>38°C), or acute illness within 24 hours prior to any study vaccination (Participant may be enrolled 24 hours after resolution of these symptoms).\n2. History of suspected or laboratory-confirmed VZV infection\n3. Close contact or household exposure to an individual with suspected or laboratory-confirmed VZV infection within 4 weeks prior to the first study vaccination.\n4. Household member(s) considered at high risk of severe VZV infection, including:\n\n   * Immunocompromised individuals\n   * Pregnant women or newborn infants whose mothers lack history of varicella infection or varicella vaccination\n   * Newborn infants born at \\\u003C 28 weeks gestational age.\n5. History of congenital, hereditary, acquired immunodeficiency, or autoimmune disease.\n6. History of bleeding disorder or thrombocytopenia contraindicating subcutaneous vaccination, based on the investigator's judgment.\n7. History of hypersensitivity and severe allergic reaction (e.g., anaphylaxis) to any vaccines or to any components of the study intervention, including gelatin or neomycin.\n8. History of Guillain-Barre syndrome following receipt of any prior vaccines.\n9. Active untreated tuberculosis infection.\n10. Significant unstable chronic or acute illness that, in the investigator's judgment, could pose a risk to the participant's safety, interfere with protocol-specified procedures, or complicate the interpretation of study results.\n11. Any other medical conditions that, in the opinion of the investigator, might interfere with the evaluation of study objectives (e.g., major congenital anomalies, neurological disorders, history of seizure disorders)\n\n    Prior\u002FConcomitant therapy\n12. Prior receipt of any varicella-containing vaccine.\n13. Receipt of any vaccine within 4 weeks prior to the first study vaccination, except influenza vaccine, which may be received ≥ 2 weeks prior, and pneumococcal conjugate vaccine (PCV), for which the last dose of the primary series must have been administered ≥ 8 weeks prior to the first study vaccination.\n14. Receipt of any live-attenuated vaccine within 4 weeks prior to the first study vaccination, or planned receipt of any live-attenuated vaccine through 4 weeks following each study vaccination, if not administered on the same day as the study vaccine.\n15. Receipt of antiviral medications within 4 weeks prior to the first study vaccination, or planned use of antiviral medications at any time during the study through 6 weeks following the second vaccination.\n16. Receipt of salicylates within 2 weeks prior to the first study vaccination, or planned use of salicylates at any time during the study through 6 weeks following the second vaccination.\n17. Receipt of immunoglobulins (except for BeyfortusTM \\[nirsevimab\\]) or any blood products within 24 weeks prior to the first study vaccination, or planned receipt at any time during the study period.\n18. Receipt or planned chronic use (defined as \\> 2 consecutive weeks) of systemic immunosuppressive therapy or immune-modifying medications, including anti-cancer chemotherapy, radiation therapy; or systemic corticosteroids (equivalent to ≥ 1 mg\u002Fkg\u002Fday of prednisone or 20 mg\u002Fday for individuals weighing \\>10 kg) within 24 weeks prior to the first study vaccination throughout the end of the study period (Use of inhaled, topical, or intranasal glucocorticoids is permitted).\n\n    Prior\u002FConcurrent Clinical Study Experience\n19. Participation in another clinical study involving study intervention within 4 weeks (6 months in Korea in accordance with local regulations) prior to the first study vaccination, or concurrent \u002F planned participation in another clinical study involving study intervention during this study.\n\n    Other Exclusions\n20. Investigators, study staff directly involved in conducting the study or supervised by the investigator, and their respective family members.",true,"ALL","12 Months","12 Years",{"count":21,"type":22},780,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The goal of this study is to evaluate the safety and immunogenicity of an investigational varicella vaccine in children. Researchers will compare the investigational vaccine, NBP608, with licensed varicella vaccines. The study includes children aged 12 months to 12 years.\n\nApproximately 780 participants will take part in this study. Participants will be randomly assigned to receive either the investigational vaccine (NBP608) or licensed varicella vaccines. Some participants will receive two doses, while others will receive one dose, according to the assigned study group.\n\nParticipants will:\n\nReceive two subcutaneous injections of a study vaccine, administered approximately three months apart (if applicable).\n\nVisit the study clinic seven times over approximately 15 months. Receive follow-up phone calls 7 days after each vaccination to monitor for safety.",[28],"Varicella (Chickenpox)",[30,31,32,33,34],"SKYVaricella","NBP608","Varicella vaccine","Chickenpox vaccine","Pediatric vaccination","NOT_YET_RECRUITING","2026-06-11",{"date":38,"type":39},"2026-06-15","ACTUAL",{"date":41,"type":22},"2026-06-05",{"date":43,"type":22},"2028-01-02",{"name":45,"class":46},"SK Bioscience Co., Ltd.","INDUSTRY",15,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":55,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100629342","phase-3-immunogenicity-and-safety-of-varicella-vaccine-live-in-healthy-vietnamese-children-100629342","NCT07473427","Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children","Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial","Inclusion Criteria:\n\n1. Healthy children aged 1-12 years;\n2. Vaccination history:\n\n   * Participants aged 1 year old: no vaccination history with any varicella containing vaccine;\n   * Participants aged 2\\~12 years old: no vaccination history with any varicella containing vaccine, or have received 1 dose of varicella vaccine at least 3 months before enrollment;\n3. Participants and\u002For their legal guardians are able to understand and sign the informed consent\u002Fassent voluntarily;\n4. Participants are able to comply with the study procedures based on the assessment of the investigator;\n5. Participants should provide verifiable identification, to be contacted, and to contact the investigator during the study period.\n\nExclusion Criteria:\n\n1. Prior history of VZV infection;\n2. Have been exposed to VZV at home, day care, school, etc. within 4 weeks before enrollment;\n3. Known allergy to vaccines or vaccine ingredients, or serious adverse reactions to vaccines, such as urticaria, dyspnea, angioneurotic edema;\n4. Autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection);\n5. Coagulation disorders (e.g. factor deficiency, platelet disorders), or history of bleeding, hematoma, or bruising following intramuscular injections or venipuncture;\n6. Poorly controlled chronic illnesses or history of severe diseases that, including but not limited to cardiovascular diseases, hematological disorders, liver and kidney diseases, digestive system disorders, respiratory diseases, malignancies, and a history of major organ transplantation;\n7. Any confirmed or suspected syphilis, hepatitis B or hepatitis C infection;\n8. Current or history of severe neurological diseases (epilepsy, convulsions or seizures \\[excluding history of febrile seizures\\]) or psychiatric disorders, or presence of a family history of psychiatric disorders;\n9. Receipt of ≥14 days of immunosuppressive or other immunomodulatory therapy (prednisone ≥20mg\u002Fday, or prednisone ≥2mg\u002Fkg\u002Fday, or its equivalent), cytotoxic therapy within 180 days prior to screening, or plans for such treatment during the trial;\n10. Receipt of blood products or immunoglobulins within 180 days prior to screening, or plans to receive these treatments in the trial;\n11. Receipt of other investigational drugs\u002Fvaccines within 30 days prior to screening, or plans to receive such drugs or vaccines during the study period;\n12. Receipt of attenuated live vaccines or nucleic acid vaccines within 28 days prior to screening, or subunit or inactivated vaccines within 7 days prior to screening;\n13. Fever on vaccination day, with axillary temperature \\>37.2°C pre-vaccination, or vital signs outside normal range, or failure to pass physical examination;\n14. Presence of skin injuries, inflammation, ulcers, rashes, scars, or other conditions at the intended injection site that may interfere with drug administration or observation of local reactions;\n15. Acute onset of various acute diseases or chronic diseases within the past 7 days, or known or suspected active infections;\n16. Any other factors considered by the investigator to make the participant unsuitable for participation in the trial.","1 Year",{"count":57,"type":22},300,[25],"This is a single armed, Phase 3 study to assess the immunogenicity and safety of the varicella vaccine manufactured by Sinovac. A total of 300 healthy participants aged 1-12 years will be enrolled. All participants will receive a single dose of varicella vaccine manufactured by Sinovac.",[28,61],"Varicella Immunisation","2026-06-10",{"date":64,"type":39},"2026-06-12",{"date":38,"type":22},{"date":67,"type":22},"2026-10-01",{"name":69,"class":46},"Sinovac (Dalian) Vaccine Technology Co., Ltd.",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":70},"100597100","phase-3-a-study-to-evaluate-immunogenicity-and-safety-after-the-first-and-second-doses-of-mg1111-barycela-inj-in-healthy-children-aged-12-months-to-12-years-100597100","NCT07054099","A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years","A Phase III, Double-blind, Randomized, Multicenter, Multinational, Active-controlled, Non-inferiority Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years","Inclusion Criteria:\n\n* Participant must be 12 months to 12 years of age, inclusive, at the time of signing the informed consent or assent.\n* Participant is overtly healthy as determined by the investigator\n\nExclusion Criteria:\n\n* Participants with a history of exposure to varicella through contact with a varicella patient at home, school, or childcare facility within 4 weeks before Screening\n* Participants with a history of varicella infection and varicella vaccine, either licensed or investigational, and either standalone or any combination, such as MMRV\n* Participants with acute moderate or severe infection with or without fever at the time of dosing\n* Participants who have had any suspected allergy symptoms, such as systemic rash, during the 72 hours before each administration of investigational product",{"count":79,"type":22},474,[25],"This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up to 10 years to monitor varicella infection.",[28,83],"Chickenpox Vaccine","RECRUITING","2026-04-14",{"date":87,"type":39},"2026-04-17",{"date":89,"type":39},"2026-03-17",{"date":91,"type":22},"2036-07",{"name":93,"class":46},"GC Biopharma Corp",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":16,"sex":17,"minAge":101,"maxAge":19,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":5},"100629463","phase-3-second-dose-of-varicella-vaccine-in-healthy-children-100629463","NCT07475000","Second Dose of Varicella Vaccine in Healthy Children","Immunogenicity and Safety of the Second Dose of Varicella Vaccine in Healthy Children: An Open-label Study","Inclusion Criteria:\n\n1. Healthy children aged 15 months to 12 years.\n2. Have received one dose of varicella vaccine at 12 months of age in Turkey (verified by vaccination card or official electronic immunization record).\n3. Written informed consent obtained from parent(s) or legally authorized representative(s); assent obtained from children as applicable according to local regulations.\n4. Able to comply with study procedures, as assessed by the investigator.\n5. Able to provide verifiable identification and be contacted for study follow-up during the study period.\n\nExclusion Criteria:\n\n1. History of varicella-zoster virus (VZV) infection (based on parental report or medical record).\n2. Known exposure to VZV within 4 weeks prior to screening.\n3. Receipt of more than one dose of varicella vaccine.\n4. Interval between first dose of varicella vaccine and enrollment less than 3 months.\n5. Known allergy to any vaccine component or history of severe allergic reaction to any vaccine (e.g., urticaria, dyspnea, angioedema).\n6. Known or suspected immunodeficiency or autoimmune disease (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid disease, asplenia, functional asplenia, or HIV infection).\n7. Poorly controlled chronic disease or history of severe systemic disease.\n8. Current or history of severe neurological disorders (e.g., epilepsy, convulsions or seizures excluding simple febrile seizures) or psychiatric disorders.\n9. Receipt of ≥14 days of immunosuppressive or immunomodulatory therapy (e.g., prednisone ≥20 mg\u002Fday or ≥2 mg\u002Fkg\u002Fday or equivalent), or cytotoxic therapy within 180 days prior to screening, or planned use during the study period.\n10. Receipt of blood products or immunoglobulins within 180 days prior to screening, or planned receipt during the study period.\n11. Receipt of other investigational drugs or vaccines within 30 days prior to screening, or planned receipt during the study period.\n12. Receipt of live attenuated or nucleic acid vaccines within 28 days prior to screening, or subunit or inactivated vaccines within 7 days prior to screening.\n13. Fever (axillary temperature \\>37.2°C), abnormal vital signs, or clinically significant abnormal findings on physical examination on the day of vaccination.\n14. Skin conditions at the intended injection site (e.g., inflammation, ulceration, rash, scar, or other conditions that may interfere with administration or safety assessment).\n15. Acute illness or exacerbation of chronic disease within 7 days prior to vaccination, or known or suspected active infection.\n16. Any condition that, in the opinion of the investigator, would make the participant unsuitable for participation in the study.","15 Months",{"count":57,"type":22},[25],"This study aim to assess the immunogenicity and safety of interchangeable administration of the second dose of varicella vaccine. A total of 300 healthy participants aged 15 months - 12 years will be enrolled. Written informed consent form will be obtained from participants' parents or legally acceptable representatives (and assents will be obtained from participants aged above 9 years old and written consent forms will be prepared and consent will be obtained in writing if possible from the participants aged 3-8 years old.) before enrollment. Participants will be assigned to 5 groups according to the brand of first dose varicella vaccine they received at the age of 12 months. All participants will receive the second dose of varicella vaccine manufactured by Sinovac.\n\nThe duration of individual participation from enrollment to the last onsite visit will be a maximum of 42 days. The end of study is considered the completion of the last visit for the last participant in this study.\n\nBlood samples (2.5 - 3.0ml per time) for immunogenicity assessment will be collected. The blood samples will be collected before vaccination and 42 days after vaccination.",[28,61],"2026-03-11",{"date":108,"type":39},"2026-03-16",{"date":110,"type":39},"2026-01-28",{"date":112,"type":22},"2026-11-15",{"name":69,"class":46},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":16,"sex":17,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":70},"100584632","phase-4-study-of-live-attenuated-varicella-vaccine-co-administered-with-mmr-vaccine-or-dtap-vaccine-100584632","NCT06891872","Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine","Immunogenicity and Safety of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine in Healthy Children Aged 18~24 Months: an Open-label, Randomized, Phase Ⅳ Study Clinical Trial","Inclusion Criteria:\n\n* Infants aged 18-24 months;\n* have completed 3 doses of DTaP for primary immunization in their first year of life without the fourth dose of Dtap-containing vaccine;\n* have completed the first dose of MMR in their first year of life without a second dose of MMR;\n* Guardians of participants who are able to understand and voluntarily sign informed consent;\n* Provision of legal proof of identity.\n\nExclusion Criteria:\n\n* Having a history of previous varicella vaccination;\n* Having a history of chickenpox, pertussis, diphtheria, tetanus, measles, mumps, and rubella;\n* Having a history of uncontrolled chronic or serious diseases, including but not limited to cardiovascular diseases, hematological diseases, liver and kidney diseases, digestive diseases, respiratory diseases, malignant tumors, major functional organ transplantation, etc.;\n* Presence of autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid disease, asplenia, functional asplenia, HIV infection);\n* Presence of abnormal coagulation function (e.g. coagulation factor deficiency, platelet abnormality);\n* Having\u002FPrevious having a severe neurological disorder (epilepsy, seizures, or convulsions) or psychosis, or have a family history of psychosis;\n* Acute onset of various acute or chronic illnesses within the last 7 days, or known or suspected active infection;\n* Receipt of \\> 14 days of immunosuppressive or other immunomodulatory therapy (prednisone ≥2 mg\u002Fkg\u002F day or its equivalent, except topical or inhaled corticosteroids), cytotoxic therapy within the past 6 months, or planned to receive such therapy during the trial;\n* Having received immune globulin or other blood products within the past 3 months or plan to receive such treatment during the trial;\n* Receipt of another study drug or vaccine within the past 30 days or plans to receive such drug or vaccine during the trial;\n* Administration of live attenuated vaccine within the past 28 days or subunit, inactivated, or other process vaccine within the past 7 days;\n* Known allergies to the vaccine or vaccine components, such as urticaria after vaccination, dyspnea, angioedema;\n* Having fever on the day of scheduled vaccination (axillary temperature \\> 37.0 ° C);\n* Failure of medical examination on the planned vaccination day;\n* Participants have any other factors that, in the judgment of the investigator, make them ineligible to participate in a clinical trial.","18 Months","24 Months",{"count":124,"type":22},720,[126],"PHASE4","This is a phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The primary objective of this study is to evaluate the immunogenicity of live attenuated varicella vaccine co-administered with MMR vaccine or DTaP vaccine. The secondary objective is to evaluate the safety of the vaccines when administered simultaneously.",[129,130,131],"Varicella (chickenpox)","MMR Vaccine","DTaP Vaccine",[133,134],"Co-administered","VZV","2025-03-17",{"date":137,"type":39},"2025-03-24",{"date":139,"type":22},"2025-05",{"date":141,"type":22},"2025-12",{"name":69,"class":46}]